A recently published molecular testing guideline for EGFR mutations suggested that laboratories are strongly encouraged to use sensitive methods that are able to detect mutations in specimens with as little as 10% cancer cells [28], However, our results indicated that both DS and MtS methods have strengths and weaknesses and could potentially miss part of EGFR-mutant patients. This evidence concerns the gene EGFR and cancer.